BAC
Bank of America Corporation
BAC has lower modeled downside risk, despite its lower overall score.
NU
Nu Holdings Ltd.
NU has the edge over BAC overall, supported by stronger valuation and stronger modeled upside.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
NU Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| N/A | |
| N/A |
NU's revenue and profitability are currently strong. Free cash flow and net leverage aren't meaningful measures for financial services companies like NU.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
NU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $11.83 | — |
| Current | 16x | $11.83 | — |
| Cheap | 23x | $17.04 | +44% |
| Fair | 33x | $24.31 | +106% |
| Expensive | 125x | $92.38 | +681% |
Historical ranges are pointers, not guarantees.
NU has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
NU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for NU, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
NU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.06 | +43% |
| Q2 2026 | $0.74 | +61% |
| Q1 2026 | $0.65 | +51% |
| Q4 2025 | $0.58 | +45% |
| Q3 2025 | $0.51 | +42% |
| Q2 2025 | $0.46 | +48% |
| Q1 2025 | $0.43 | +65% |
| Q4 2024 | $0.40 | +90% |
| Q3 2024 | $0.36 | +350% |
NU has the edge over BAC on earnings, with stronger typical year-over-year growth.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over NU on profitability, with a higher operating margin.
NU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.5B | +50% |
| Q1 2026 | $5B | +53% |
| Q4 2025 | $4.7B | +65% |
| Q3 2025 | $4.2B | +46% |
| Q2 2025 | $3.7B | +34% |
| Q1 2025 | $3.2B | +23% |
| Q4 2024 | $2.9B | +24% |
| Q3 2024 | $2.9B | +34% |
NU has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 22% | -1.5 points |
| Q1 2026 | 19% | -5.3 points |
| Q4 2025 | 23% | -3.9 points |
| Q3 2025 | 27% | +1.4 points |
| Q2 2025 | 24% | -2.5 points |
| Q1 2025 | 24% | +2.6 points |
| Q4 2024 | 27% | +2.5 points |
| Q3 2024 | 25% | +6.1 points |
NU's operating margin was 22% last quarter, down 1.5 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over NU on cash generation, producing positive trailing cash flow while its opponent burns cash.
NU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.9B | -218% |
| Q1 2026 | -$1.3B | -229% |
| Q4 2025 | $1.1B | -14% |
| Q3 2025 | -$1.1B | +$8.8M |
| Q2 2025 | $2.5B | -6.3% |
| Q1 2025 | $1B | +$1.6B |
| Q4 2024 | $1.3B | -52% |
| Q3 2024 | -$1.1B | +$2.2B |
NU's free cash flow was −$4.2B over the past year, against $3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like NU.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over NU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
NU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -5.4M shares |
| 1 year | +0.1% | +5.1M shares |
| 3 years | +1.3% | +61M shares |
| 5 years | +6.4% | +296M shares |
| Available history | +6.4% | +296M shares |
NU has 4.9B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $500.4M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NU spent $500M buying back its own shares over the past year, after none the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
NU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 5.0x | High |
| Q1 2026 | -3.9x | Net Cash |
| Q4 2025 | -2.5x | Net Cash |
| Q3 2025 | -3.9x | Net Cash |
| Q2 2025 | -4.6x | Net Cash |
| Q1 2025 | -4.3x | Net Cash |
| Q4 2024 | -4.4x | Net Cash |
| Q3 2024 | -4.3x | Net Cash |
NU has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
NU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.1 | Neutral |
| Stochastic | 10.5 | Oversold |
NU's weekly RSI is 41 (neutral) and its Stochastic is 11 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over NU on valuation relative to its sector.
NU PE vs Financial Services Sector
| Metric | NU | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 13x | 23% above |
| PE % | 1 | 63 | 62 pts below |
NU is trading at 16x earnings, a 23% premium to the Financial Services sector's median of 13x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
NU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.5 | 13% below |
| 20 week MA | $14.0 | 15% below |
| 50 week MA | $14.6 | 19% below |
| 100 week MA | $13.8 | 14% below |
| 200 week MA | $11.7 | 1.5% above |
NU has fallen below most of its moving averages, though it's still 1.5% above its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over NU on returns for 2026, with the stronger performance.
NU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $11.9 | $9.83 | -17% |
| 2022 | $9.83 | $3.89 | -60% |
| 2023 | $3.89 | $8.33 | +114% |
| 2024 | $8.33 | $10.3 | +24% |
| 2025 | $10.3 | $16.8 | +62% |
| 2026 YTD | $16.8 | $11.8 | -29% |
NU's yearly returns have swung widely, from +114% in 2023 to −60% in 2022. It's down 29% so far in 2026.